Azelis posts resilient Q1 as acquisitions mask organic slowdown and cash flow strengthens

Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance

Novo Nordisk posts strong late-stage results for oral diabetes pill in children and teens

The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c

Eli Lilly posts strong Phase 3 win for Jaypirca combo in blood cancer trial

Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors

GSK Pharma shareholders back Ronojit Biswas’ Board, CFO appointment via postal ballot

Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker

Biocon Foundation, BeST Cluster and NCBS launch first BioWISE Cohort for postgraduate women students

Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship

Torrent Pharmaceuticals posts Rs. 577 Cr Q3 profit; nine-month earnings jump to Rs. 1,725 Cr

Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY

The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore

IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY

Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics

Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore

SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track

The company’s EBITDA margin remained resilient above 20%